Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

2,242 total articles

Buy FMCB for Defensive Income and Modest Re-rating Potential in 2026

Buy FMCB for Defensive Income and Modest Re-rating Potential in 2026

Farmers & Merchants Bancorp (FMCB) looks like a conservative regional bank trade for 2026: strong earnings, an established dividend track record, and an expanded buyback program support a modest re-rating. Thin liquidity and near-term technical overbought readings argue for a disciplined entry, a modest stop, and a patient long-term horizon.

Marfrig (MBRFY) Upgrade: Buy for a 2026 Rebound, Not a Quick Flip

Marfrig (MBRFY) Upgrade: Buy for a 2026 Rebound, Not a Quick Flip

Marfrig Global Foods (MBRFY) looks cheap on headline multiples, yields nearly 12% and is trading above its near-term moving averages. I’m upgrading the rating to a buy for a 2026 earnings recovery trade. Entry near $3.95, target $5.25 and stop $3.10 — plan for a long-term hold into 2026 (up to 180 trading days) while watching margin signals and com…

GROY: Positioning for a Cash-Flow Inflection and Structural Rerate

GROY: Positioning for a Cash-Flow Inflection and Structural Rerate

Gold Royalty (GROY) sits at an interesting crossroads: a leaner balance sheet, an expanded revolving facility, and an accelerating royalty-generator pipeline that has grown to 250 assets. With the stock trading at $4.60 and technicals showing constructive momentum, the risk/reward favors a long exposure to a potential cash-flow inflection and struc…

Equillium: EQ504 Is the Hook — The Platform Could Be the Real Upside

Equillium: EQ504 Is the Hook — The Platform Could Be the Real Upside

Equillium is a clinical-stage biotech with a multi-cytokine pipeline anchored by EQ504 (AhR modulation for ulcerative colitis) and complementary assets (EQ001, EQ302). The stock trades around $1.83 with a market cap near $111M and roughly $10.7M in cash. Upcoming UC-focused KOL engagement, partnership work on an oral EQ302 formulation and improving…

Buy SentinelOne on the Dip - AI Endpoint Security at a Rare Discount

Buy SentinelOne on the Dip - AI Endpoint Security at a Rare Discount

SentinelOne (S) has been punished in 2025-26 despite clear market tailwinds for AI-powered endpoint protection. With a $4.39B market cap, positive free cash flow, and improving partner checks, the current price near $12.92 represents an asymmetric trade: meaningful upside if execution normalizes, limited downside to structural problems. This trade …

CrowdStrike: Buy the Panic — AI Fears Have Been Overblown

CrowdStrike: Buy the Panic — AI Fears Have Been Overblown

CrowdStrike (CRWD) has been punished disproportionately in the recent SaaS/AI rotation. The company's cloud-native platform, growing FCF, and positive channel checks make the current pullback a high-probability entry for a mid-term rebound. This trade recommends a long with a clear entry at $363.18, stop at $320.00 and a target of $460.00 over ~45 …

PayPal at a Price That Demands a Second Look

PayPal at a Price That Demands a Second Look

PayPal trades like a broken growth story but still generates meaningful cash and earnings. At roughly $47 and ~8x earnings, the risk/reward favors a long position for patient buyers who can tolerate execution and legal risk. Trade plan: enter $47.00, stop $40.00, target $70.00 over a 180-trading-day horizon.

Four Business Days That Decide the Deal: A Trade on Warner Bros. Discovery Ahead of Netflix's Match Window

Four Business Days That Decide the Deal: A Trade on Warner Bros. Discovery Ahead of Netflix's Match Window

Warner Bros. Discovery sits squarely in the crosshairs of a bidding duel. Paramount Skydance raised its cash offer to $31 per share, triggering a four-business-day matching window for Netflix. WBD is trading near $29.02 with a market cap near $72.3B and enterprise value about $101.5B. This trade plan captures the near-term binary around the match d…

Newmont After the Rout: A Tactical Long While Gold Regroups

Newmont After the Rout: A Tactical Long While Gold Regroups

Newmont (NEM) has been hammered alongside metal prices, but the company's free cash flow, low leverage and production profile argue for a controlled long trade. This is a mid-term trade idea: enter near current levels, target a retest of the recent high, and use a hard stop below visible support. The plan assumes gold stabilizes or recovers modestl…

Blackstone: Play the Private-Markets Rebound From Near-Term Lows

Blackstone: Play the Private-Markets Rebound From Near-Term Lows

Blackstone is trading near its 52-week low after a period of private-credit anxiety and broad selling in asset managers. With a $144B market cap, double-digit ROE and $3.65B in free cash flow, BX offers a way to ride a private-markets rebound. This trade idea lays out a concrete entry at $116.41, a $105 stop and a $150 target over a 180 trading-day…

Buy SES AI Now — Betting on Software-Led Scaling in Li‑Metal Batteries

Buy SES AI Now — Betting on Software-Led Scaling in Li‑Metal Batteries

SES AI is transitioning from a pure-play cell maker to an integrated Li‑metal battery platform that pairs manufacturing with AI-driven materials discovery and subscription software. With a market cap near $613M and an enterprise value of roughly $560M, the risk/reward looks asymmetric if the company converts Molecular Universe 1.0 into recurring re…